Fertility drug REKOVELLE® under the microscope in Real-World study

NCT ID NCT05499052

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study observed 201 women in Nordic countries and Switzerland who were using the fertility drug REKOVELLE® for the first time during IVF or ICSI. Researchers tracked how doctors prescribed the drug, including dose adjustments and use of a dosing app, to understand real-world patterns. The goal was to gather information on effectiveness and safety without changing standard care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFERTILITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ferring Investigational Site

    Copenhagen, Denmark

  • Ferring Investigational Site

    Horsens, Denmark

  • Ferring Investigational Site

    Køge, Denmark

  • Ferring Investigational Site

    Odense, Denmark

  • Ferring Investigational Site

    Søborg, Denmark

  • Ferring Investigational Site

    Skien, Norway

  • Ferring Investigational Site

    Malmö, Sweden

  • Ferring Investigational Site

    Baden, Switzerland

  • Ferring Investigational Site

    Basel, Switzerland